158 related articles for article (PubMed ID: 37455019)
1. Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma.
Gao F; Liu H; Meng X; Liu J; Wang J; Yu J; Liu X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Golchehre Z; Chavoshzadeh Z; He J; Zhang H; Wang X
Br J Haematol; 2023 Sep; 202(6):1151-1164. PubMed ID: 37455019
[TBL] [Abstract][Full Text] [Related]
2. Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome.
Muntañola A; Mozas P; Mercadal S; Huguet M; Bobillo S; Bastos-Oreiro M; Jiménez-Ubieto A; Rovira J; Rivero A; Tolosa C; Luizaga L; de Villambrosia SG; Novelli S; Caballero D; Salar A; Alonso-Álvarez S; Magnano L; Gutiérrez NC; Sancho JM; López-Guillermo A;
Br J Haematol; 2023 Feb; 200(3):306-314. PubMed ID: 36261137
[TBL] [Abstract][Full Text] [Related]
3. Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy.
Mir F; Mattiello F; Grigg A; Herold M; Hiddemann W; Marcus R; Seymour JF; Bolen CR; Knapp A; Nielsen T; Casulo C
Am J Hematol; 2020 Dec; 95(12):1503-1510. PubMed ID: 32815559
[TBL] [Abstract][Full Text] [Related]
4. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
Casulo C; Dixon JG; Le-Rademacher J; Hoster E; Hochster HS; Hiddemann W; Marcus R; Kimby E; Herold M; Sebban C; Gyan E; Foon K; Nielsen T; Vitolo U; Salles GA; Shi Q; Flowers CR
Blood; 2022 Mar; 139(11):1684-1693. PubMed ID: 34614146
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL.
Ye X; Fan X; Cui R; Mu J; Liu M; Lyu C; Li Y; Chen L; Zhang J; Li X; Wang J; Mou N; Deng Q
Ann Hematol; 2023 Jul; 102(7):1789-1799. PubMed ID: 37171599
[TBL] [Abstract][Full Text] [Related]
6. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
Sortais C; Lok A; Tessoulin B; Gastinne T; Mahé B; Dubruille V; Blin N; Touzeau C; Moreau A; Bossard C; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Chevallier P; Moreau P; Leux C; Le Gouill S
Ann Hematol; 2020 Jul; 99(7):1595-1604. PubMed ID: 32417940
[TBL] [Abstract][Full Text] [Related]
7. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.
Jurinovic V; Kridel R; Staiger AM; Szczepanowski M; Horn H; Dreyling MH; Rosenwald A; Ott G; Klapper W; Zelenetz AD; Barr PM; Friedberg JW; Ansell S; Sehn LH; Connors JM; Gascoyne RD; Hiddemann W; Unterhalt M; Weinstock DM; Weigert O
Blood; 2016 Aug; 128(8):1112-20. PubMed ID: 27418643
[TBL] [Abstract][Full Text] [Related]
8. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
Russler-Germain DA; Krysiak K; Ramirez C; Mosior M; Watkins MP; Gomez F; Skidmore ZL; Trani L; Gao F; Geyer S; Cashen AF; Mehta-Shah N; Kahl BS; Bartlett NL; Alderuccio JP; Lossos IS; Ondrejka SL; Hsi ED; Martin P; Leonard JP; Griffith M; Griffith OL; Fehniger TA
Blood Adv; 2023 Sep; 7(18):5524-5539. PubMed ID: 37493986
[TBL] [Abstract][Full Text] [Related]
9. Expression of glucose transporter-1 in follicular lymphoma affected tumor-infiltrating immunocytes and was related to progression of disease within 24 months.
Deng Y; Ma J; Zhao S; Yang M; Sun Y; Zhang Q
Transl Oncol; 2023 Feb; 28():101614. PubMed ID: 36584488
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis.
Gao F; Zhang T; Liu H; Li W; Liu X; Qiu L; Li L; Zhou S; Qian Z; Dong S; Zhao S; Wang X; Zhang H
Ann Hematol; 2022 Nov; 101(11):2383-2392. PubMed ID: 36029326
[TBL] [Abstract][Full Text] [Related]
11. Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcome.
Bitansky G; Avigdor A; Vasilev E; Zlotnick M; Ribakovsky E; Benjamini O; Nagler A; Kedmi M
Leuk Lymphoma; 2020 Nov; 61(11):2645-2651. PubMed ID: 32643497
[TBL] [Abstract][Full Text] [Related]
12. Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.
Tobin JWD; Keane C; Gunawardana J; Mollee P; Birch S; Hoang T; Lee J; Li L; Huang L; Murigneux V; Fink JL; Matigian N; Vari F; Francis S; Kridel R; Weigert O; Haebe S; Jurinovic V; Klapper W; Steidl C; Sehn LH; Law SC; Wykes MN; Gandhi MK
J Clin Oncol; 2019 Dec; 37(34):3300-3309. PubMed ID: 31461379
[TBL] [Abstract][Full Text] [Related]
13. External Validation of the FLIPI Risk Score Measured at Diagnosis and POD24 Among Individuals With Follicular Lymphoma at the Time of Subsequent Relapse.
Boyne DJ; Chua N; Owen C; Joe-Uzuegbu O; Shakir H; Gogna P; Jarada TN; Brenner DR; Elia-Pacitti J; Ewara EM; Cheung WY
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):e277-e285. PubMed ID: 37331847
[TBL] [Abstract][Full Text] [Related]
14. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy.
Rodríguez-Sevilla JJ; Fernández-Rodríguez C; Bento L; Diez-Feijóo R; Pinzón S; Gibert J; Fernández-Ibarrondo L; Lafuente M; Ferrer A; Sánchez-González B; Gimeno E; Sainz J; Ramos R; García JF; Colomo L; Bellosillo B; Gutiérrez A; Salar A
Blood Adv; 2023 Apr; 7(8):1606-1614. PubMed ID: 36260737
[TBL] [Abstract][Full Text] [Related]
16. Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors.
Mozas P; López C; Grau M; Nadeu F; Clot G; Valle S; Kulis M; Navarro A; Ramis-Zaldivar JE; González-Farré B; Rivas-Delgado A; Rivero A; Frigola G; Balagué O; Giné E; Delgado J; Villamor N; Matutes E; Magnano L; García-Sanz R; Huet S; Russell RB; Campo E; López-Guillermo A; Beà S
Hematol Oncol; 2023 Oct; 41(4):631-643. PubMed ID: 36994552
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression.
Montoto S; López-Guillermo A; Altés A; Perea G; Ferrer A; Camós M; Villela L; Bosch F; Esteve J; Cervantes F; Bladé J; Nomdedeu B; Campo E; Sierra J; Montserrat E
Ann Oncol; 2004 Oct; 15(10):1484-9. PubMed ID: 15367408
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study.
Fernández-Miranda I; Pedrosa L; Llanos M; Franco FF; Gómez S; Martín-Acosta P; García-Arroyo FR; Gumá J; Horcajo B; Ballesteros AK; Gálvez L; Martínez N; Marín M; Sequero S; Navarro M; Yanguas-Casás N; Calvo V; Rueda-Domínguez A; Provencio M; Sánchez-Beato M
Clin Cancer Res; 2023 Jan; 29(1):209-220. PubMed ID: 36269794
[TBL] [Abstract][Full Text] [Related]
19. EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment.
Szumera-CieĆkiewicz A; Poleszczuk J; Paszkiewicz-Kozik E; Rymkiewicz G; SokÓŁ K; Borysiuk A; Kotarska M; Owczarek D; Kawecka M; Pytlak B; Walewski J; Prochorec-Sobieszek M
Anticancer Res; 2020 Dec; 40(12):6685-6697. PubMed ID: 33288562
[TBL] [Abstract][Full Text] [Related]
20. Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry.
Liu L; Yu X; Li Z; He X; Zha J; Lin Z; Hong Y; Zheng H; Lai Q; Ding K; Jia X; Fu G; Yu H; Yang H; Li Z; Young KH; Xu B
J Hematol Oncol; 2022 Aug; 15(1):115. PubMed ID: 35996180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
